Evaluation of the Effects of Empagliflozin on Serum Levels of Triglycerides and Cholesterol in Patients with Type 2 Diabetes Mellitus and Hypertriglyceridemia: A Prospective Study
نویسندگان
1 Universal Scientific and Research Network (USERN), Lorestan University of Medical Sciences, Khorramabad, Iran.
2 Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran. Surgery Education and Researching Network (SERGN), Universal Scientific and Research Network (USERN), Khorramabad, Iran.
3 Department of Internal Medicine, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.
4 Department of Internal Medicine, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.
doi
10.18502/ijdo.v16i4.17287چکیده
Objective: Sodium-glucose cotransporter -2 (SGLT2) inhibitors may improve lipid panels in addition to lowering blood sugar. This research examined how empagliflozin, an SGLT2 inhibitor, affected triglycerides in type 2 diabetes mellitus (T2DM) patients with hypertriglyceridemia. Materials and Methods: This prospective study was conducted at the Endocrinology Clinic of Shahid Rahimi Hospital ...
